Byun, J. M., Min, C., Kim, K., Yoon, D. H., Jung, S., Chng, W., Nagarajan, C., Koh, Y. (2025). Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1. Blood. https://doi.org/10.1182/blood-2025-5835